$GEB Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in INOVIO PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in INOVIO PHARMACEUTICALS, INC.. Get notifications about new insider transactions in INOVIO PHARMACEUTICALS, INC. for free.
Page: < prev 1 2 3 4 5 6 next >
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 139,745 | 0 | 2,143,902 | 2 M to 2.1 M (+6.97 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 6.61 | 17,787 | 117,572 | 2,004,157 | 2 M to 2 M (-0.88 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 57,334 | 0 | 2,021,944 | 2 M to 2 M (+2.92 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 0.00 | 61,300 | 0 | 61,300 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 6.68 | 100,000 | 668,000 | 100,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | M | 0.00 | 25,000 | 0 | 50,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Payment of Exercise | F | 6.61 | 9,171 | 60,620 | 47,048 | 56.2 K to 47 K (-16.31 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | M | 0.00 | 25,000 | 0 | 56,219 | 31.2 K to 56.2 K (+80.08 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 0.00 | 35,000 | 0 | 35,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 6.68 | 60,000 | 400,800 | 60,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | M | 0.00 | 10,000 | 0 | 20,000 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | M | 0.00 | 5,334 | 0 | 10,666 | |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Buy | M | 0.00 | 10,000 | 0 | 738,956 | 729 K to 739 K (+1.37 %) |
| Mar 13 2017 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Buy | M | 0.00 | 5,334 | 0 | 728,956 | 723.6 K to 729 K (+0.74 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Payment of Exercise | F | 6.95 | 3,067 | 21,316 | 63,513 | 66.6 K to 63.5 K (-4.61 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 0.00 | 8,333 | 0 | 66,580 | 58.2 K to 66.6 K (+14.31 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Payment of Exercise | F | 6.95 | 3,640 | 25,298 | 31,219 | 34.9 K to 31.2 K (-10.44 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | M | 0.00 | 8,333 | 0 | 34,859 | 26.5 K to 34.9 K (+31.41 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | M | 0.00 | 8,333 | 0 | 8,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Payment of Exercise | F | 6.95 | 3,067 | 21,316 | 25,758 | 28.8 K to 25.8 K (-10.64 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Buy | M | 0.00 | 8,333 | 0 | 28,825 | 20.5 K to 28.8 K (+40.66 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 0.00 | 13,333 | 0 | 13,333 | |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 6.95 | 4,365 | 30,337 | 1,964,610 | 2 M to 2 M (-0.22 %) |
| Mar 07 2017 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 13,333 | 0 | 1,968,975 | 2 M to 2 M (+0.68 %) |
| Jan 04 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 6.12 | 3,680 | 22,522 | 0 | |
| Jan 04 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 6.12 | 6,133 | 37,534 | 0 | |
| Jan 04 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 6.12 | 3,680 | 22,522 | 58,247 | 54.6 K to 58.2 K (+6.74 %) |
| Jan 04 2017 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 6.12 | 6,133 | 37,534 | 54,567 | 48.4 K to 54.6 K (+12.66 %) |
| Aug 30 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 6.12 | 33,116 | 202,670 | 0 | |
| Aug 30 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Sell | S | 9.30 | 21,800 | 202,733 | 48,434 | 70.2 K to 48.4 K (-31.04 %) |
| Aug 30 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 6.12 | 33,116 | 202,670 | 70,234 | 37.1 K to 70.2 K (+89.22 %) |
| Jun 29 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.13 | 10,000 | 91,309 | 142,291 | 132.3 K to 142.3 K (+7.56 %) |
| Jun 29 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.13 | 10,000 | 91,309 | 142,291 | 132.3 K to 142.3 K (+7.56 %) |
| Jun 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 5.08 | 245,300 | 1,246,124 | 0 | |
| Jun 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 11.24 | 110,866 | 1,246,134 | 1,955,642 | 2.1 M to 2 M (-5.36 %) |
| Jun 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 5.08 | 245,300 | 1,246,124 | 2,066,508 | 1.8 M to 2.1 M (+13.47 %) |
| Jun 06 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| Jun 06 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 18 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | M | 8.92 | 6,250 | 55,750 | 0 | |
| May 18 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Sell | S | 10.37 | 6,250 | 64,819 | 17,798 | 24 K to 17.8 K (-25.99 %) |
| May 18 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Buy | M | 8.92 | 6,250 | 55,750 | 24,048 | 17.8 K to 24 K (+35.12 %) |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | A | 9.33 | 10,000 | 93,300 | 10,000 | |
| May 16 2016 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | A | 0.00 | 10,000 | 0 | 10,000 | |
| May 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 0.00 | 23,334 | 0 | 46,666 | |
| May 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 9.52 | 9,098 | 86,613 | 1,821,208 | 1.8 M to 1.8 M (-0.50 %) |
| May 10 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 23,334 | 0 | 1,830,306 | 1.8 M to 1.8 M (+1.29 %) |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | M | 0.00 | 5,000 | 0 | 132,291 | 127.3 K to 132.3 K (+3.93 %) |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Buy | M | 0.00 | 5,000 | 0 | 63,333 | 58.3 K to 63.3 K (+8.57 %) |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Buy | M | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Buy | M | 0.00 | 5,000 | 0 | 41,750 | 36.8 K to 41.8 K (+13.61 %) |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Buy | M | 0.00 | 5,000 | 0 | 17,798 | 12.8 K to 17.8 K (+39.07 %) |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | M | 0.00 | 5,000 | 0 | 0 | |
| May 09 2016 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Buy | M | 0.00 | 5,000 | 0 | 5,000 | 0 to 5 K |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 0.00 | 30,000 | 0 | 30,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 0.00 | 16,000 | 0 | 16,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 7.02 | 30,000 | 210,600 | 30,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Weiner David B. | Director | Option Exercise | A | 7.02 | 16,000 | 112,320 | 16,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 0.00 | 172,000 | 0 | 172,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 7.02 | 172,000 | 1,207,440 | 172,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 7.02 | 67,500 | 473,850 | 67,500 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 7.02 | 67,500 | 473,850 | 67,500 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 0.00 | 75,000 | 0 | 75,000 | |
| Mar 11 2016 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 7.02 | 67,500 | 473,850 | 67,500 | |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | M | 0.00 | 13,334 | 0 | 26,666 | |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Payment of Exercise | F | 7.48 | 4,440 | 33,211 | 1,806,972 | 1.8 M to 1.8 M (-0.25 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | M | 0.00 | 13,334 | 0 | 1,811,412 | 1.8 M to 1.8 M (+0.74 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | M | 0.00 | 8,334 | 0 | 16,666 | |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Payment of Exercise | F | 7.48 | 2,842 | 21,258 | 20,492 | 23.3 K to 20.5 K (-12.18 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Buy | M | 0.00 | 8,334 | 0 | 23,334 | 15 K to 23.3 K (+55.56 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | M | 0.00 | 8,334 | 0 | 16,666 | |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Payment of Exercise | F | 7.48 | 3,216 | 24,056 | 37,118 | 40.3 K to 37.1 K (-7.97 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | M | 0.00 | 8,334 | 0 | 40,334 | 32 K to 40.3 K (+26.04 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | M | 0.00 | 8,334 | 0 | 16,666 | |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Payment of Exercise | F | 7.48 | 3,196 | 23,906 | 26,526 | 29.7 K to 26.5 K (-10.75 %) |
| Mar 08 2016 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | M | 0.00 | 8,334 | 0 | 29,722 | 21.4 K to 29.7 K (+38.97 %) |
| Apr 18 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.49 | 28,000 | 265,700 | 64,750 | 36.8 K to 64.8 K (+76.19 %) |
| Apr 18 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.57 | 28,000 | 267,960 | 64,750 | 36.8 K to 64.8 K (+76.19 %) |
| Apr 18 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.46 | 4,200 | 39,720 | 6,650 | 2.5 K to 6.7 K (+171.43 %) |
| Apr 18 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.49 | 2,000 | 18,979 | 6,450 | 4.5 K to 6.5 K (+44.94 %) |
| Apr 18 2016 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.45 | 6,200 | 58,565 | 28,700 | 22.5 K to 28.7 K (+27.56 %) |
| Sep 30 2015 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | P | 5.50 | 4,000 | 22,000 | 32,000 | 28 K to 32 K (+14.29 %) |
| Aug 17 2015 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Buy | P | 7.21 | 6,000 | 43,258 | 12,798 | 6.8 K to 12.8 K (+88.26 %) |
| Aug 03 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | X | 5.08 | 306,625 | 1,557,655 | 0 | |
| Aug 03 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | X | 5.08 | 306,625 | 1,557,655 | 1,798,078 | 1.5 M to 1.8 M (+20.56 %) |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 8.01 | 40,000 | 320,400 | 40,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 0.00 | 70,000 | 0 | 70,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | A | 8.01 | 7,500 | 60,075 | 7,500 | |
| May 08 2015 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | A | 0.00 | 5,000 | 0 | 5,000 | |
| Apr 13 2015 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Buy | P | 9.53 | 8,000 | 76,240 | 36,750 | 28.8 K to 36.8 K (+27.83 %) |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 7.56 | 60,000 | 453,600 | 60,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 7.56 | 85,000 | 642,600 | 85,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 0.00 | 40,000 | 0 | 40,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 7.56 | 60,000 | 453,600 | 60,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 7.56 | 60,000 | 453,600 | 60,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 0.00 | 25,000 | 0 | 25,000 | |
| Mar 09 2015 | GEB | INOVIO PHARMACEUTI ... | Wysenski Nancy | Director | Option Exercise | A | 7.56 | 18,750 | 141,750 | 18,750 | |
| Oct 09 2014 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Buy | P | 10.10 | 3,960 | 39,996 | 21,388 | 17.4 K to 21.4 K (+22.72 %) |
| Aug 22 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 10.01 | 4,000 | 40,045 | 36,750 | 32.8 K to 36.8 K (+12.21 %) |
| Aug 22 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 10.01 | 4,000 | 40,045 | 36,750 | 32.8 K to 36.8 K (+12.21 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.75 | 14,000 | 136,461 | 32,750 | 18.8 K to 32.8 K (+74.67 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.75 | 14,000 | 136,461 | 32,750 | 18.8 K to 32.8 K (+74.67 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.72 | 1,800 | 17,496 | 2,675 | 875 to 2.7 K (+205.71 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.73 | 1,700 | 16,541 | 4,450 | 2.8 K to 4.5 K (+61.82 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.73 | 4,500 | 43,785 | 173,066 | 168.6 K to 173.1 K (+2.67 %) |
| Aug 21 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Buy | P | 9.71 | 4,600 | 44,649 | 168,566 | 164 K to 168.6 K (+2.81 %) |
| Aug 12 2014 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | P | 9.06 | 250,000 | 2,263,750 | 1,750,000 | 1.5 M to 1.8 M (+16.67 %) |
| Aug 12 2014 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Buy | P | 8.70 | 2,550 | 22,185 | 28,000 | 25.5 K to 28 K (+10.02 %) |
| May 27 2014 | GEB | INOVIO PHARMACEUTI ... | DHILLON AVTAR S | Director | Option Exercise | A | 2.20 | 40,000 | 88,000 | 40,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Option Exercise | A | 2.20 | 340,000 | 748,000 | 340,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | Sardesai Niranjan | Chief Operating Off ... | Option Exercise | A | 2.20 | 155,000 | 341,000 | 155,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 2.20 | 155,000 | 341,000 | 155,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 2.20 | 155,000 | 341,000 | 155,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | BENITO SIMON X | Director | Option Exercise | A | 2.20 | 40,000 | 88,000 | 40,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | Cabrera Angel | Director | Option Exercise | A | 2.20 | 40,000 | 88,000 | 40,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | COLLINS MORTON | Director | Option Exercise | A | 2.20 | 40,000 | 88,000 | 40,000 | |
| May 23 2014 | GEB | INOVIO PHARMACEUTI ... | MAHMOUD ADEL | Director | Option Exercise | A | 2.20 | 40,000 | 88,000 | 40,000 | |
| Apr 15 2014 | GEB | INOVIO PHARMACEUTI ... | Kim Jong Joseph | Chief Executive Off ... | Buy | P | 2.25 | 25,000 | 56,250 | 5,965,809 | 5.9 M to 6 M (+0.42 %) |
| Mar 27 2014 | GEB | INOVIO PHARMACEUTI ... | Bagarazzi Mark | Chief Medical Offic ... | Option Exercise | A | 3.23 | 150,000 | 484,500 | 150,000 | |
| Mar 27 2014 | GEB | INOVIO PHARMACEUTI ... | KIES PETER | CFO | Option Exercise | A | 3.23 | 150,000 | 484,500 | 150,000 |